Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Berg Balance Scale
研究概览
简要总结
Charcot-Marie-Tooth (CMT) disease is caused by a genetic abnormality involving the PMP22 gene, resulting in demyelination of the peripheral nerves. Demyelination leads to sensorimotor impairment and causes progressive muscle weakness and tendon contractures, initially affecting the lower limbs. Consequently, individuals with CMT experience balance impairments and gait disturbances, including ankle instability, foot drop, and postural instability, which lead to frequent falls and reduced quality of life. Currently, there is no disease-modifying treatment for CMT.
Several rehabilitation approaches have been proposed, including endurance training and muscle strengthening programs, to improve independence in activities of daily living. However, rehabilitation practices for individuals with CMT remain poorly standardized, and there is still a lack of clearly defined rehabilitation protocols, despite broad agreement among healthcare professionals regarding their potential benefits.
More recently, noninvasive focal tendon vibration has been investigated in several neurological disorders to improve sensory function, balance, and motor performance. Previous studies suggest that mechanical vibratory stimulation applied to the quadriceps tendon may induce sustained improvements in postural control and lower-limb muscle strength.
The present study aims to evaluate a rehabilitation program combined with tendon vibratory stimulation. The objective is to compare the effectiveness of a short-term (2-week), intensive multidisciplinary rehabilitation program focused on balance with different types of focal tendon vibration, in order to better address balance impairments and their associated complications in individuals with Charcot-Marie-Tooth disease.
详细描述
Charcot-Marie-Tooth (CMT) disease is the most common inherited peripheral neuropathy, with a prevalence ranging from 3.1 to 82.3 per 100,000 individuals. It is caused by genetic abnormalities affecting peripheral nerves. The most common form, accounting for approximately 60% of CMT cases, is Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A is characterized by a demyelinating neuropathy, autosomal dominant inheritance, and a mutation involving the PMP22 gene.
The first clinical signs of the disease typically appear before the age of 20 years and consist of a length-dependent sensorimotor impairment with distal predominance and diffuse areflexia. The disease primarily affects the lower limbs; upper limb involvement is variable and may develop after several years of disease progression. These impairments result in progressive distal muscle weakness associated with muscle atrophy, tendon contractures leading to pes cavus and claw toe deformities, and mild-to-moderate distal sensory impairment. These manifestations lead to major functional complaints among individuals with CMT, including balance disorders, gait disturbances related to ankle instability, foot clearance difficulties during the swing phase, and postural instability, resulting in frequent falls and impaired quality of life.
Currently, there is no disease-modifying treatment for CMT.
Assistive devices and lower-limb orthotic management may be prescribed. Surgical treatment may be considered in cases of severe and disabling musculoskeletal deformities.
Several rehabilitation approaches have been proposed, including endurance training and strengthening programs to improve independence in activities of daily living, as well as aerobic training programs aimed at improving functional capacity, aerobic capacity, muscle strength, and fatigue in individuals with CMT. The French National Diagnostic and Care Protocol (PNDS) for hereditary motor and sensory neuropathies associated with CMT highlights the lack of standardized rehabilitation practices and clearly defined protocols, despite a consensus among healthcare professionals regarding their potential benefits. Indeed, the literature includes only one randomized controlled trial, published in 2006, with a small sample size (n = 16), demonstrating improvements in balance, assessed using the Berg Balance Scale (BBS), following a two-week dynamic training program combining passive stretching, muscle strengthening, and standing balance exercises.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17 (17p11.2).
- •Age between 18 and 65 years.
- •Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs.
- •Affiliation with a social security/health insurance system.
- •Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks.
排除标准
- •Comorbidities causing peripheral neuropathy (e.g., diabetes, renal failure, medication-induced neuropathy).
- •Balance or gait disorders due to another cause.
- •Individuals without a permanent residence.
- •Individuals deprived of liberty by judicial or administrative decision or under legal guardianship.
- •Individuals unable to understand the study objectives and procedures or unable to provide informed consent.
- •Individuals unable to complete all study procedures.
- •Previous use of the Vibramoov device.
- •Pregnant women or women planning to become pregnant during the study period.
- •Concurrent participation in another research study.
研究组 & 干预措施
With mechanical vibratory stimulation
干预措施: Multidisciplinary rehabilitation program (Other)
Without mechanical vibratory stimulation
干预措施: Multidisciplinary rehabilitation program (Other)
结局指标
主要结局
Berg Balance Scale
时间窗: At enrollment, at the end of rehabilitation, 5 weeks after the end of rehabilitation, 13 weeks after the end of rehabilitation
The primary outcome measure of this study will be the assessment of balance using the Berg Balance Scale (BBS). The BBS is a 14-item scale in which each item is scored from 0 to 4 points and evaluates static and dynamic balance as well as fall risk. This scale has been validated in individuals with neurological disorders and has been used to assess balance impairments in individuals with Charcot-Marie-Tooth disease. The BBS has demonstrated good reliability and responsiveness to change. A change of 4 to 7 points, depending on the baseline score, has been identified as a clinically meaningful indicator of improvement in balance.
Berg Balance Scale
时间窗: Baseline, Week 3 , Week 7, Week 15
The primary outcome measure of this study will be the assessment of balance using the Berg Balance Scale (BBS). The BBS is a 14-item scale in which each item is scored from 0 to 4 points and evaluates static and dynamic balance as well as fall risk. This scale has been validated in individuals with neurological disorders and has been used to assess balance impairments in individuals with Charcot-Marie-Tooth disease. The BBS has demonstrated good reliability and responsiveness to change. A change of 4 to 7 points, depending on the baseline score, has been identified as a clinically meaningful indicator of improvement in balance.
次要结局
- CMT Neuropathy Score(At enrollment, at the end of rehabilitation, 5 weeks after the end of rehabilitation, 13 weeks after the end of rehabilitation)
- Gait assessment(Baseline, Week 3, Week 7, Week 15)
- CMT Neuropathy Score(Baseline, Week 3 , Week 7, Week 15)
- Posturography(Baseline, Week 3, Week 7, Week 15)
- Timed Up and Go (TUG) test(Baseline, Week 3, Week 7, Week 15)
- Knee joint position sense assessment using electronic goniometers(Baseline, Week 3, Week 7, Week 15)
- Walking speed(Baseline, Week3, Week 7, Week 15)
- Borg Rate of Perceived Extorsion (RPE) scale(Baseline, Week 3, Week 7, Week 15)
- Muscle strength assessment(Baseline, Week 3, Week 7, Week 15)
- Patient-Reported Outcome: R-ODS questionnaire(Baseline, Week 3, Week 7, Week 15)
- Patient-Reported Outcome: FSS Scale(Baseline, Week 3, Week 7, Week 15)
- Patient-Reported Outcome: QoL NMD v1.0(Baseline, Week 3, Week 7, Week 15)
- Patient-reported Outcome: NRS Scale(Baseline, Week 3, Week 7, Week 15)
